Free Trial
NYSE:VEEV

Veeva Systems (VEEV) Stock Price, News & Analysis

Veeva Systems logo
$287.61 +4.20 (+1.48%)
As of 03:58 PM Eastern

About Veeva Systems Stock (NYSE:VEEV)

Key Stats

Today's Range
$282.65
$288.13
50-Day Range
$215.85
$289.99
52-Week Range
$177.41
$291.69
Volume
1.28 million shs
Average Volume
1.15 million shs
Market Capitalization
$47.00 billion
P/E Ratio
60.93
Dividend Yield
N/A
Price Target
$269.80
Consensus Rating
Moderate Buy

Company Overview

Veeva Systems, Inc. (NYSE:VEEV) is a cloud-computing company focused on delivering software solutions tailored to the life sciences industry. Founded in 2007 by Peter Gassner and a team of industry veterans, Veeva offers a suite of applications designed to streamline clinical, regulatory, quality, and commercial operations for pharmaceutical, biotechnology, and medical device organizations. Its software-as-a-service (SaaS) model enables companies to manage content, data, and business processes in a secure, compliant environment.

The company’s flagship offering, Veeva Vault, provides a cloud-based content management platform that supports a wide range of functions such as clinical trial operations, regulatory submissions, quality management, and safety management. Veeva CRM, another core product, equips commercial teams with customer relationship management tools optimized for healthcare professionals and key accounts. Additional solutions include Veeva Network for master data management, Veeva Nitro for life sciences data analytics, and Veeva OpenData for global healthcare professional and organization reference data.

With headquarters in Pleasanton, California, Veeva has expanded its global footprint through offices in North America, Europe, Asia Pacific, Latin America, and Japan. The company serves thousands of customers ranging from large multinational pharmaceutical firms to emerging biotech companies. Its industry-specific focus allows Veeva to incorporate regulatory guidance and best practices directly into its applications, helping clients accelerate drug development, ensure product quality, and optimize commercial performance on a global scale.

Under the leadership of CEO Peter Gassner and a seasoned executive team, Veeva has maintained a strong commitment to innovation and customer success. The company invests heavily in research and development to extend its platform capabilities, often partnering with life sciences organizations to address emerging challenges such as digital regulatory submissions and real-world evidence generation. Since its initial public offering in 2013, Veeva has grown both organically and through strategic acquisitions, reinforcing its position as a leading provider of cloud software for the life sciences sector.

AI Generated. May Contain Errors.

Veeva Systems Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

VEEV MarketRank™: 

Veeva Systems scored higher than 83% of companies evaluated by MarketBeat, and ranked 182nd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Veeva Systems has received a consensus rating of Moderate Buy. The company's average rating score is 2.52, and is based on 15 buy ratings, 8 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Veeva Systems has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Veeva Systems' stock forecast and price target.
  • Earnings Growth

    Earnings for Veeva Systems are expected to grow by 6.67% in the coming year, from $4.35 to $4.64 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Veeva Systems is 58.92, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.90.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Veeva Systems is 58.92, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.46.

  • Price to Earnings Growth Ratio

    Veeva Systems has a PEG Ratio of 2.24. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Veeva Systems has a P/B Ratio of 8.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Veeva Systems' valuation and earnings.
  • Percentage of Shares Shorted

    3.38% of the float of Veeva Systems has been sold short.
  • Short Interest Ratio / Days to Cover

    Veeva Systems has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Veeva Systems has recently decreased by 6.94%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Veeva Systems does not currently pay a dividend.

  • Dividend Growth

    Veeva Systems does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.38% of the float of Veeva Systems has been sold short.
  • Short Interest Ratio / Days to Cover

    Veeva Systems has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Veeva Systems has recently decreased by 6.94%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Veeva Systems has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 28 news articles for Veeva Systems this week, compared to 19 articles on an average week.
  • Search Interest

    21 people have searched for VEEV on MarketBeat in the last 30 days. This is an increase of 62% compared to the previous 30 days.
  • MarketBeat Follows

    Only 10 people have added Veeva Systems to their MarketBeat watchlist in the last 30 days. This is a decrease of -23% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Veeva Systems insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,376,179.00 in company stock.

  • Percentage Held by Insiders

    10.30% of the stock of Veeva Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    88.20% of the stock of Veeva Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Veeva Systems' insider trading history.
Receive VEEV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veeva Systems and its competitors with MarketBeat's FREE daily newsletter.

VEEV Stock News Headlines

VEEV - Veeva Systems Inc Class A Financials - Morningstar
379 passengers walked away from this
Elon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving lives in aviation — it’s solving the biggest flaw in AI. And only one U.S. company has the patent.
Veeva and AWS Expand 10-Year Relationship
See More Headlines

VEEV Stock Analysis - Frequently Asked Questions

Veeva Systems' stock was trading at $210.25 at the beginning of the year. Since then, VEEV shares have increased by 36.8% and is now trading at $287.61.
View the best growth stocks for 2025 here
.

Veeva Systems Inc. (NYSE:VEEV) posted its earnings results on Wednesday, May, 28th. The technology company reported $1.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.74 by $0.23. The firm's revenue for the quarter was up 16.7% on a year-over-year basis.
Read the conference call transcript
.

Veeva Systems subsidiaries include these companies: Veeva RTSM, Veracity Logic, Learnaboutgmp, Physicians World, Veeva Crossix, Zinc Ahead Ltd, Selligy, and AdvantageMS.

Shares of VEEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Veeva Systems investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM).

Company Calendar

Last Earnings
5/28/2025
Today
6/30/2025
Next Earnings (Estimated)
8/27/2025
Fiscal Year End
1/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Computer Software
Current Symbol
NYSE:VEEV
Employees
5,480
Year Founded
2007

Price Target and Rating

Average Stock Price Target
$269.80
High Stock Price Target
$329.00
Low Stock Price Target
$192.00
Potential Upside/Downside
-6.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.52
Research Coverage
25 Analysts

Profitability

Trailing P/E Ratio
60.93
Forward P/E Ratio
66.12
P/E Growth
2.24
Net Income
$714.14 million
Pretax Margin
35.42%

Debt

Sales & Book Value

Annual Sales
$2.75 billion
Cash Flow
$4.84 per share
Price / Cash Flow
59.42
Book Value
$35.87 per share
Price / Book
8.02

Miscellaneous

Free Float
146,581,000
Market Cap
$47.00 billion
Optionable
Optionable
Beta
0.99

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NYSE:VEEV) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners